RDUS [NASD]
Radius Health, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own1.00% Shs Outstand47.44M Perf Week2.74%
Market Cap266.70M Forward P/E23.08 EPS next Y0.26 Insider Trans- Shs Float47.17M Perf Month-12.79%
Income-72.70M PEG- EPS next Q0.05 Inst Own- Short Float19.13% Perf Quarter-26.38%
Sales216.90M P/S1.23 EPS this Y36.80% Inst Trans5.19% Short Ratio10.99 Perf Half Y-66.01%
Book/sh-5.61 P/B- EPS next Y206.90% ROA-40.70% Target Price8.67 Perf Year-69.83%
Cash/sh- P/C- EPS next 5Y29.60% ROE29.40% 52W Range4.97 - 23.00 Perf YTD-13.29%
Dividend- P/FCF- EPS past 5Y18.90% ROI-60.60% 52W High-73.91% Beta1.06
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin91.10% 52W Low20.72% ATR0.49
Employees293 Current Ratio1.80 Sales Q/Q-23.30% Oper. Margin-25.20% RSI (14)41.12 Volatility7.34% 8.45%
OptionableYes Debt/Eq- EPS Q/Q-14.90% Profit Margin-33.50% Rel Volume0.82 Prev Close5.93
ShortableYes LT Debt/Eq- EarningsMay 05 BMO Payout- Avg Volume820.89K Price6.00
Recom3.30 SMA20-3.10% SMA50-19.93% SMA200-44.40% Volume670,878 Change1.18%
May-23-22Initiated SVB Leerink Mkt Perform $7
Dec-10-21Downgrade Morgan Stanley Equal-Weight → Underweight $18 → $7
Dec-10-21Downgrade Goldman Buy → Neutral $33 → $12
Dec-03-21Initiated BofA Securities Underperform $16
Mar-22-21Resumed Goldman Buy $33
Feb-24-21Reiterated H.C. Wainwright Neutral $22 → $25
Sep-29-20Resumed JP Morgan Neutral $23
Jul-08-20Downgrade SVB Leerink Outperform → Mkt Perform $17
May-13-20Downgrade Morgan Stanley Overweight → Equal-Weight $20
Apr-24-20Initiated Stifel Hold $20
Aug-29-19Upgrade Citigroup Neutral → Buy $24 → $40
May-30-19Resumed Citigroup Neutral
May-29-19Upgrade Goldman Neutral → Buy
Feb-14-19Initiated H.C. Wainwright Neutral $22
Mar-29-18Initiated Leerink Partners Outperform $53
Jan-29-18Initiated Morgan Stanley Overweight $57
Dec-06-17Initiated Citigroup Neutral $30
Oct-06-17Resumed Goldman Neutral
Mar-24-17Reiterated H.C. Wainwright Buy $71 → $66
Sep-21-16Reiterated H.C. Wainwright Buy $55 → $71
May-20-22 12:54PM  
09:46AM  
09:00AM  
08:52AM  
04:17AM  
03:57AM  
May-19-22 05:00PM  
May-06-22 01:30PM  
12:43PM  
May-05-22 08:45AM  
07:30AM  
06:47AM  
Apr-28-22 03:02PM  
Apr-25-22 08:30AM  
Apr-05-22 08:00AM  
Mar-16-22 08:30AM  
Mar-08-22 08:30AM  
Mar-07-22 08:30AM  
Mar-03-22 04:05PM  
Mar-01-22 10:00AM  
08:00AM  
Feb-25-22 11:03AM  
Feb-24-22 06:30PM  
09:05AM  
07:30AM  
Feb-17-22 03:02PM  
Feb-15-22 12:00PM  
Feb-07-22 01:17PM  
Jan-13-22 09:00AM  
Jan-10-22 08:57AM  
Dec-23-21 10:41AM  
08:30AM  
Dec-20-21 08:32AM  
Dec-17-21 12:38AM  
Dec-15-21 09:38PM  
Dec-10-21 09:38PM  
Dec-09-21 09:13AM  
Dec-08-21 01:33PM  
10:15AM  
09:00AM  
09:00AM  
Nov-17-21 03:01AM  
Nov-11-21 08:30AM  
Nov-09-21 09:08AM  
Nov-08-21 07:00PM  
09:15AM  
08:00AM  
Nov-01-21 03:01PM  
Oct-29-21 08:57AM  
Oct-21-21 01:15PM  
10:14AM  
Oct-20-21 03:00PM  
12:18PM  
12:08PM  
08:30AM  
08:22AM  
Oct-19-21 10:57AM  
Oct-18-21 08:30AM  
Oct-04-21 08:45AM  
Sep-30-21 06:03AM  
Sep-28-21 10:11AM  
09:54AM  
Sep-27-21 07:21AM  
Sep-22-21 08:00AM  
Aug-09-21 09:46AM  
Aug-07-21 09:01AM  
Aug-06-21 11:26AM  
Aug-05-21 08:45AM  
07:00AM  
Jul-29-21 03:05PM  
Jul-27-21 08:00AM  
Jul-23-21 11:12AM  
Jul-22-21 09:00AM  
Jul-20-21 05:11PM  
12:43AM  
Jun-02-21 08:15AM  
May-11-21 07:50AM  
May-10-21 02:18PM  
May-07-21 10:01PM  
07:45AM  
06:45AM  
06:30AM  
Apr-30-21 03:00PM  
Apr-22-21 08:15AM  
Apr-20-21 04:30PM  
Mar-27-21 11:31AM  
Mar-24-21 08:00AM  
Mar-23-21 09:19AM  
Mar-03-21 04:15PM  
Feb-26-21 12:08PM  
08:58AM  
Feb-25-21 05:01PM  
07:00AM  
Feb-17-21 08:30AM  
Feb-16-21 08:30AM  
Feb-12-21 12:33PM  
09:32AM  
Feb-09-21 09:29AM  
06:28AM  
Jan-25-21 10:34AM  
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerMay 18Buy5.57477,8242,661,0028,733,538May 20 11:35 AM
BIOTECH TARGET N V10% OwnerJan 06Buy6.31300,0001,894,4108,255,714Jan 07 11:33 AM
BIOTECH TARGET N V10% OwnerJan 05Buy6.30250,0001,574,6507,955,714Jan 07 11:33 AM
Rubric Capital Management LP10% OwnerDec 16Buy7.07146,6851,037,7526,959,305Dec 16 05:32 PM
Rubric Capital Management LP10% OwnerDec 15Buy6.77180,7441,223,6376,812,620Dec 15 05:22 PM
Rubric Capital Management LP10% OwnerDec 14Buy6.8194,103640,9366,631,876Dec 15 05:22 PM
Rubric Capital Management LP10% OwnerDec 13Buy7.08187,3911,326,8036,537,773Dec 15 05:22 PM
Rubric Capital Management LP10% OwnerDec 10Buy7.17768,1715,511,6276,350,382Dec 10 06:01 PM
Rubric Capital Management LP10% OwnerDec 09Buy7.58264,6442,007,0875,582,211Dec 10 06:01 PM
Rubric Capital Management LP10% OwnerDec 08Buy8.02560,6914,497,0785,317,567Dec 10 06:01 PM
BIOTECH TARGET N V10% OwnerSep 29Buy12.95100,0001,294,5007,705,714Oct 01 10:34 AM
BIOTECH TARGET N V10% OwnerSep 22Buy12.28150,0001,841,2807,605,714Sep 24 11:58 AM